S100 Beta Protein as a Marker of Hepatic Encephalopathy: A Breakthrough in Diagnostics or a False Trail? Review of the Literature.

[1] Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014; 60: 715–735. VilstrupH AmodioP BajajJ CordobaJ FerenciP MullenKD WeissenbornK WongP Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver Hepatology 2014 60 715 735 10.1002/hep.2721025042402 Search in Google Scholar

[2] Schomerus H, Hamster W. Quality of life in cirrhotics with minimal hepatic encephalopathy. Metab Brain Dis. 2001; 16: 37–41. SchomerusH HamsterW Quality of life in cirrhotics with minimal hepatic encephalopathy Metab Brain Dis 2001 16 37 41 10.1023/A:101161042784311726087 Search in Google Scholar

[3] Ong JP, Aggarwal A, Krieger D, Aggarwal A, Krieger D, Easley KA, Karafa MT, Van Lente F, Arroliga AC, Mullen KD. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med. 2003; 114: 188–193. OngJP AggarwalA KriegerD AggarwalA KriegerD EasleyKA KarafaMT Van LenteF ArroligaAC MullenKD Correlation between ammonia levels and the severity of hepatic encephalopathy Am J Med 2003 114 188 193 10.1016/S0002-9343(02)01477-8 Search in Google Scholar

[4] Qureshi MO, Khokhar N, Shafqat F. Ammonia levels and the severity of hepatic encephalopathy. J Coll Physicians Surg Pak. 2014; 24: 160–163. QureshiMO KhokharN ShafqatF Ammonia levels and the severity of hepatic encephalopathy J Coll Physicians Surg Pak 2014 24 160 163 Search in Google Scholar

[5] Romero-Gómez M. Pharmacotherapy of hepatic encephalopathy in cirrhosis. Expert Opin Pharmacother. 2010; 11: 1317–1327. Romero-GómezM Pharmacotherapy of hepatic encephalopathy in cirrhosis Expert Opin Pharmacother 2010 11 1317 1327 10.1517/1465656100372472120384539 Search in Google Scholar

[6] Jones EA. Ammonia, the GABA neurotransmitter system, and hepatic encephalopathy. Metab Brain Dis. 2002; 17: 275–281. JonesEA Ammonia, the GABA neurotransmitter system, and hepatic encephalopathy Metab Brain Dis 2002 17 275 281 10.1023/A:102194961642212602504 Search in Google Scholar

[7] Moore BW. A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun. 1965; 19: 739–744. MooreBW A soluble protein characteristic of the nervous system Biochem Biophys Res Commun 1965 19 739 744 10.1016/0006-291X(65)90320-74953930 Search in Google Scholar

[8] Böttiger BW, Möbes S, Glätzer R, Bauer H, Gries A, Bärtsch P, Motsch J, Martin E. Astroglial protein S-100 is an early and sensitive marker of hypoxic brain damage and outcome after cardiac arrest in humans. Circulation. 2001; 103: 2694–2698. BöttigerBW MöbesS GlätzerR BauerH GriesA BärtschP MotschJ MartinE Astroglial protein S-100 is an early and sensitive marker of hypoxic brain damage and outcome after cardiac arrest in humans Circulation 2001 103 2694 2698 10.1161/01.CIR.103.22.2694 Search in Google Scholar

[9] Allampati S, Duarte-Rojo A, Thacker LR, Patidar KR, White MB, Klair JS, John B, Heuman DM, Wade JB, Flud C. Diagnosis of minimal hepatic encephalopathy using Stroop EncephalApp: A multicenter US-based, norm-based study. Am J Gastroenterol. 2016; 111: 78–86. AllampatiS Duarte-RojoA ThackerLR PatidarKR WhiteMB KlairJS JohnB HeumanDM WadeJB FludC Diagnosis of minimal hepatic encephalopathy using Stroop EncephalApp: A multicenter US-based, norm-based study Am J Gastroenterol 2016 111 78 86 10.1038/ajg.2015.37726644276 Search in Google Scholar

[10] Sen J, Belli A. S100B in neuropathologic states: The CRP of the brain? J Neurosci Res. 2007; 85: 1373–1380. SenJ BelliA S100B in neuropathologic states: The CRP of the brain? J Neurosci Res 2007 85 1373 1380 10.1002/jnr.2121117348038 Search in Google Scholar

[11] Ikeda Y, Umemura K. Analysis of reference values of serum S100B concentrations of Japanese adults. Rinsho Byori. 2005; 53: 395–399. IkedaY UmemuraK Analysis of reference values of serum S100B concentrations of Japanese adults Rinsho Byori 2005 53 395 399 Search in Google Scholar

[12] Undén J, Ingebrigtsen T, Romner B. Scandinavian guidelines for initial management of minimal, mild and moderate head injuries in adults: an evidence and consensus-based update. BMC Med. 2013; 11: 50. UndénJ IngebrigtsenT RomnerB Scandinavian guidelines for initial management of minimal, mild and moderate head injuries in adults: an evidence and consensus-based update BMC Med 2013 11 50 10.1186/1741-7015-11-50362184223432764 Search in Google Scholar

[13] Foerch C, Singer OC, Neumann-Haefelin T, du Mesnil de Rochemont R, Steinmetz H, Sitzer M. Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. Arch Neurol. 2005; 62: 1130. FoerchC SingerOC Neumann-HaefelinT du Mesnil de RochemontR SteinmetzH SitzerM Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction Arch Neurol 2005 62 1130 10.1001/archneur.62.7.113016009772 Search in Google Scholar

[14] Otto M, Wiltfang J, Schutz E, Zerr I, Otto A, Pfahlberg A, Gefeller O, Uhr M, Giese A, Weber T, Kretzschmar HA, Poser S. Diagnosis of Creutzfeldt-Jakob disease by measurement of S100 protein in serum: Prospective case-control study. BMJ. 1998; 316: 577–582. OttoM WiltfangJ SchutzE ZerrI OttoA PfahlbergA GefellerO UhrM GieseA WeberT KretzschmarHA PoserS Diagnosis of Creutzfeldt-Jakob disease by measurement of S100 protein in serum: Prospective case-control study BMJ 1998 316 577 582 10.1136/bmj.316.7131.577284599518907 Search in Google Scholar

[15] Wiltfang J, Nolte W, Otto M, Wildberg J, Bahn E, Figulla HR, Pralle L, Hartmann H, Rüther E, Ramadori G. Elevated serum levels of astroglial S100beta in patients with liver cirrhosis indicate early and subclinical portal-systemic encephalopathy. Metab Brain Dis. 1999; 14: 239–251. WiltfangJ NolteW OttoM WildbergJ BahnE FigullaHR PralleL HartmannH RütherE RamadoriG Elevated serum levels of astroglial S100beta in patients with liver cirrhosis indicate early and subclinical portal-systemic encephalopathy Metab Brain Dis 1999 14 239 251 10.1023/A:1020785009005 Search in Google Scholar

[16] Vaquero J, Jordano Q, Lee WM, Blei AT. Serum protein S-100b in acute liver failure: Results of the US Acute Liver Failure Study group. Liver Transplant. 2003; 9: ajlts50172. VaqueroJ JordanoQ LeeWM BleiAT Serum protein S-100b in acute liver failure: Results of the US Acute Liver Failure Study group Liver Transplant 2003 9 ajlts50172 10.1053/jlts.2003.5017212884207 Search in Google Scholar

[17] Saleh A, Kamel L, Ghali A, Ismail A, El Khayat H. Serum levels of astroglial S100-beta and neuron-specific enolase in hepatic encephalopathy patients. East Mediterr Heal J. 2007; 13: 1114–1123. SalehA KamelL GhaliA IsmailA El KhayatH Serum levels of astroglial S100-beta and neuron-specific enolase in hepatic encephalopathy patients East Mediterr Heal J 2007 13 1114 1123 10.26719/2007.13.5.111418290405 Search in Google Scholar

[18] Isobe-Harima Y, Terai S, Segawa M, Uchida K, Yamasaki T, Sakaida I. Serum S100b (astrocyte-specific protein) is a useful marker of hepatic encephalopathy in patients with fulminant hepatitis. Liver Int. 2008; 28: 146–147. Isobe-HarimaY TeraiS SegawaM UchidaK YamasakiT SakaidaI Serum S100b (astrocyte-specific protein) is a useful marker of hepatic encephalopathy in patients with fulminant hepatitis Liver Int 2008 28 146 147 10.1111/j.1478-3231.2007.01604.x18173564 Search in Google Scholar

[19] Duarte-Rojo A, Ruiz-Margáin A, Macias-Rodriguez RU, Cubero FJ, Estradas-Trujillo J, Muñoz-Fuentes RM, Torre A. Clinical scenarios for the use of S100β as a marker of hepatic encephalopathy. World J Gastroenterol. 2016; 22: 4397. Duarte-RojoA Ruiz-MargáinA Macias-RodriguezRU CuberoFJ Estradas-TrujilloJ Muñoz-FuentesRM TorreA Clinical scenarios for the use of S100β as a marker of hepatic encephalopathy World J Gastroenterol 2016 22 4397 10.3748/wjg.v22.i17.4397485369827158209 Search in Google Scholar

[20] Strebel H, Haller B, Sohn M, Schepp W, Gundling F. Role of brain biomarkers S-100-beta and neuron-specific enolase for detection and follow-up of hepatic encephalopathy in cirrhosis before, during and after treatment with L-ornithine-L-aspartate. GE - Port J Gastroenterol. 2020; 27: 391–403. StrebelH HallerB SohnM ScheppW GundlingF Role of brain biomarkers S-100-beta and neuron-specific enolase for detection and follow-up of hepatic encephalopathy in cirrhosis before, during and after treatment with L-ornithine-L-aspartate GE - Port J Gastroenterol 2020 27 391 403 10.1159/000507225767034733251288 Search in Google Scholar

[21] Toney NA, Bell MJ, Belle SH, Hardison RM, Rodriguez-Baez N, Loomes KM, Vodovotz Y, Zamora R, Squires RS, et al. Hepatic encephalopathy in children with acute liver failure: Utility of serum neuromarkers. J Pediatr Gastroenterol Nutr. 2019; 69: 108–115. ToneyNA BellMJ BelleSH HardisonRM Rodriguez-BaezN LoomesKM VodovotzY ZamoraR SquiresRS Hepatic encephalopathy in children with acute liver failure: Utility of serum neuromarkers J Pediatr Gastroenterol Nutr 2019 69 108 115 10.1097/MPG.0000000000002351659105731058776 Search in Google Scholar